West Nile virus drug discovery

Siew Pheng Lim, Pei-Yong Shi

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

The outbreak of West Nile virus (WNV) in 1999 in the USA, and its continued spread throughout the Americas, parts of Europe, the Middle East and Africa, underscored the need for WNV antiviral development. Here, we review the current status of WNV drug discovery. A number of approaches have been used to search for inhibitors of WNV, including viral infection-based screening, enzyme-based screening, structure-based virtual screening, structure-based rationale design, and antibody-based therapy. These efforts have yielded inhibitors of viral or cellular factors that are critical for viral replication. For small molecule inhibitors, no promising preclinical candidate has been developed; most of the inhibitors could not even be advanced to the stage of hit-to-lead optimization due to their poor drug-like properties. However, several inhibitors developed for related members of the family Flaviviridae, such as dengue virus and hepatitis C virus, exhibited cross-inhibition of WNV, suggesting the possibility to re-purpose these antivirals for WNV treatment. Most promisingly, therapeutic antibodies have shown excellent efficacy in mouse model; one of such antibodies has been advanced into clinical trial. The knowledge accumulated during the past fifteen years has provided better rationale for the ongoing WNV and other flavivirus antiviral development.

Original languageEnglish (US)
Pages (from-to)2977-3006
Number of pages30
JournalViruses
Volume5
Issue number12
DOIs
StatePublished - Dec 3 2013
Externally publishedYes

Fingerprint

West Nile virus
Drug Discovery
Antiviral Agents
Antibodies
Flaviviridae
Flavivirus
Eastern Africa
Dengue Virus
Middle East
Virus Diseases
Hepacivirus
Disease Outbreaks
Clinical Trials
Enzymes
Therapeutics
Pharmaceutical Preparations

Keywords

  • Antiviral
  • Drug discovery
  • Flavivirus
  • West nile virus

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this

West Nile virus drug discovery. / Lim, Siew Pheng; Shi, Pei-Yong.

In: Viruses, Vol. 5, No. 12, 03.12.2013, p. 2977-3006.

Research output: Contribution to journalReview article

Lim, Siew Pheng ; Shi, Pei-Yong. / West Nile virus drug discovery. In: Viruses. 2013 ; Vol. 5, No. 12. pp. 2977-3006.
@article{3f9eb1b4bf014425b08c0a694ef1eb75,
title = "West Nile virus drug discovery",
abstract = "The outbreak of West Nile virus (WNV) in 1999 in the USA, and its continued spread throughout the Americas, parts of Europe, the Middle East and Africa, underscored the need for WNV antiviral development. Here, we review the current status of WNV drug discovery. A number of approaches have been used to search for inhibitors of WNV, including viral infection-based screening, enzyme-based screening, structure-based virtual screening, structure-based rationale design, and antibody-based therapy. These efforts have yielded inhibitors of viral or cellular factors that are critical for viral replication. For small molecule inhibitors, no promising preclinical candidate has been developed; most of the inhibitors could not even be advanced to the stage of hit-to-lead optimization due to their poor drug-like properties. However, several inhibitors developed for related members of the family Flaviviridae, such as dengue virus and hepatitis C virus, exhibited cross-inhibition of WNV, suggesting the possibility to re-purpose these antivirals for WNV treatment. Most promisingly, therapeutic antibodies have shown excellent efficacy in mouse model; one of such antibodies has been advanced into clinical trial. The knowledge accumulated during the past fifteen years has provided better rationale for the ongoing WNV and other flavivirus antiviral development.",
keywords = "Antiviral, Drug discovery, Flavivirus, West nile virus",
author = "Lim, {Siew Pheng} and Pei-Yong Shi",
year = "2013",
month = "12",
day = "3",
doi = "10.3390/v5122977",
language = "English (US)",
volume = "5",
pages = "2977--3006",
journal = "Viruses",
issn = "1999-4915",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "12",

}

TY - JOUR

T1 - West Nile virus drug discovery

AU - Lim, Siew Pheng

AU - Shi, Pei-Yong

PY - 2013/12/3

Y1 - 2013/12/3

N2 - The outbreak of West Nile virus (WNV) in 1999 in the USA, and its continued spread throughout the Americas, parts of Europe, the Middle East and Africa, underscored the need for WNV antiviral development. Here, we review the current status of WNV drug discovery. A number of approaches have been used to search for inhibitors of WNV, including viral infection-based screening, enzyme-based screening, structure-based virtual screening, structure-based rationale design, and antibody-based therapy. These efforts have yielded inhibitors of viral or cellular factors that are critical for viral replication. For small molecule inhibitors, no promising preclinical candidate has been developed; most of the inhibitors could not even be advanced to the stage of hit-to-lead optimization due to their poor drug-like properties. However, several inhibitors developed for related members of the family Flaviviridae, such as dengue virus and hepatitis C virus, exhibited cross-inhibition of WNV, suggesting the possibility to re-purpose these antivirals for WNV treatment. Most promisingly, therapeutic antibodies have shown excellent efficacy in mouse model; one of such antibodies has been advanced into clinical trial. The knowledge accumulated during the past fifteen years has provided better rationale for the ongoing WNV and other flavivirus antiviral development.

AB - The outbreak of West Nile virus (WNV) in 1999 in the USA, and its continued spread throughout the Americas, parts of Europe, the Middle East and Africa, underscored the need for WNV antiviral development. Here, we review the current status of WNV drug discovery. A number of approaches have been used to search for inhibitors of WNV, including viral infection-based screening, enzyme-based screening, structure-based virtual screening, structure-based rationale design, and antibody-based therapy. These efforts have yielded inhibitors of viral or cellular factors that are critical for viral replication. For small molecule inhibitors, no promising preclinical candidate has been developed; most of the inhibitors could not even be advanced to the stage of hit-to-lead optimization due to their poor drug-like properties. However, several inhibitors developed for related members of the family Flaviviridae, such as dengue virus and hepatitis C virus, exhibited cross-inhibition of WNV, suggesting the possibility to re-purpose these antivirals for WNV treatment. Most promisingly, therapeutic antibodies have shown excellent efficacy in mouse model; one of such antibodies has been advanced into clinical trial. The knowledge accumulated during the past fifteen years has provided better rationale for the ongoing WNV and other flavivirus antiviral development.

KW - Antiviral

KW - Drug discovery

KW - Flavivirus

KW - West nile virus

UR - http://www.scopus.com/inward/record.url?scp=84889599512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889599512&partnerID=8YFLogxK

U2 - 10.3390/v5122977

DO - 10.3390/v5122977

M3 - Review article

VL - 5

SP - 2977

EP - 3006

JO - Viruses

JF - Viruses

SN - 1999-4915

IS - 12

ER -